We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 79

News bytes

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • December 6 2012

Heads of the U.S. Patent and Trademark Office (USPTO), European Patent Office and Japan Patent Officecollectively known as the Trilateral Offices confirm their commitment to eliminating unnecessary duplication of work, enhancing patent examination and quality, and working to ensure that stable patent rights can be granted smoothly and easily worldwide

U.S. Supreme Court to consider just one question in Myriad Genetics

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • December 6 2012

The U.S. Supreme Court has agreed to review a Federal Circuit Court of Appeals ruling on the patentability of human genes and limited its grant of certiorari to the question “Are human genes patentable?”

CRS visiting scholar recommends that Congress clarify patentable subject matter doctrine

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 15 2012

In a Congressional Research Service paper titled “Mayo v. Prometheus: Implications for Patents, Biotechnology, and Personalized Medicine,” visiting scholar John Thomas considers how the U.S. Supreme Court ruling limiting the patentability of diagnostic methods that simply describe natural phenomena and relations may affect innovation and public health

Do DNA patents affect genetic sequencing and testing advances?

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 15 2012

University of Missouri-Kansas City School of Law Professor Christopher Holman writes in the most recent issue of Nature Technology that while DNA sequencing technology has spawned a myriad of patent-related lawsuits, “aggressive patent acquisition and enforcement practices” show no signs of abating and may not necessarily be hindering the development of next-generation DNA sequencing and analysis technologies

NGOs request march-in rights for patented drug

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 1 2012

Four non-governmental organizations (NGOs) have filed a petition with the National Institutes of Health (NIH) requesting that it grant march-in rights under the Bayh-Dole Act for a patented drug that they claim is “a federally funded invention that is much more expensive in the United States than in Canada, Europe or other high-income countries.”

Federal Circuit’s patent infringement ruling conflicts with USPTO re-examination on validity

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 1 2012

The Federal Circuit Court of Appeals has denied a request for an en banc rehearing by a medical-device patent holder which argued that the U.S. Patent and Trademark Office’s (USPTO’s) Board of Patent Appeals had effectively nullified a previous Federal Circuit decision on the validity of its patent

News bytes

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 18 2012

The U.S. Patent and Trademark Office reopens the comment period on its proposed rulemaking and proposed examination guidelines, published on July 26, 2012, “to implement the first-inventor-to-file provisions of the Leahy-Smith America Invents Act.” Comments may now be submitted until November 5

News bytes

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 3 2012

U.S. Health and Human Services Secretary Kathleen Sebelius delegates authority to the Food and Drug Administration (FDA) to determine whether clinical trial information was not submitted to the Clinical Trial Registry and Results Data Bank as required by law or “was submitted but is false or misleading in any particular.”

ACLU weighs in on patentability of human genes in Myriad Genetics

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 3 2012

American Civil Liberties Union (ACLU) attorneys representing the petitioners in The Association for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398 (U.S., docketed October 1, 2012), have filed their petition for review before the U.S. Supreme Court. Information about the Federal Circuit Court of Appeals ruling from which the petition has been filed appears in Issue 41 of this Bulletin

Moody’s claims “the worst is over” for pharmaceutical companies facing patent cliff

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 3 2012

Moody’s Investor Services has reportedly revised its outlook for the global pharmaceutical industry and upgraded it to stable, apparently anticipating that earnings will rebound in 2013 with the slowdown in patent expirations, characterized by many industry observers as the “patent cliff.”